Mankind Pharma approves Q4 and FY26 results, ₹500 crore subsidiary investment
Mankind Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Approved audited standalone and consolidated results for quarter and year ended March 31, 2026; joint auditors issued unmodified opinion.
- Approved additional investment of up to ₹500 crores in wholly owned subsidiary Mankind Medicare Private Limited, in one or more tranches.
- Board re-appointed Satish Kumar Sharma as Whole-Time Director for 5 years from September 23, 2026, subject to members' approval at 35th AGM.
Why it's rated major development: the year-on-year change is 203% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome for Please Find Attached The Audited Financial Results For The Quarter And Financial Year Ended March 31, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Mankind Pharma
- Acquisition / mergerMajor developmentMankind Pharma: FY 2025-26 results, director re-appointment, subsidiary investment
- Financial resultsMajor developmentMankind Pharma: FY26 results, director re-appointment, ₹500 crore subsidiary investment
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.